Surmodics Inc
NASDAQ:SRDX
Net Margin
Surmodics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Surmodics Inc
NASDAQ:SRDX
|
389.4m USD |
-11%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
215.6B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
174.4B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
136.5B USD |
11%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
132.9B USD |
13%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.9B USD |
13%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
57.7B USD |
8%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
48.3B EUR |
9%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
40.2B USD |
77%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
261.4B CNY |
33%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
31.2B USD |
23%
|
Surmodics Inc
Glance View
Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. The company is headquartered in Eden Prairie, Minnesota and currently employs 389 full-time employees. The firm operates through two segments: Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices, as well as drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that includes coronary, peripheral, neurovascular and structural heart, among others. The IVD segment designs, develops and manufactures component products and technologies for diagnostic immunoassay, as well as molecular tests and biomedical research applications, with products that include protein stabilization reagents, substrates, surface coatings and antigens.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Surmodics Inc's most recent financial statements, the company has Net Margin of -11.5%.
You don't have any saved screeners yet